Owen Hughes
Overview
Explore the profile of Owen Hughes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donovan J, Hamdy F, Athene Lane J, Young G, Metcalfe C, Walsh E, et al.
NEJM Evid
. 2024 Feb;
2(4):EVIDoa2300018.
PMID: 38320051
BACKGROUND: Long-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer. METHODS: Patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and...
2.
Charles R, Madhu D, Powles A, Boyde A, Hughes O, Kumar N, et al.
Front Oncol
. 2023 Sep;
13:1242560.
PMID: 37746287
Background: Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from...
3.
Hamdy F, Donovan J, Athene Lane J, Metcalfe C, Davis M, Turner E, et al.
N Engl J Med
. 2023 Mar;
388(17):1547-1558.
PMID: 36912538
Background: Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in...
4.
Lane J, Donovan J, Young G, Davis M, Walsh E, Avery K, et al.
BJU Int
. 2022 Apr;
130(3):370-380.
PMID: 35373443
Objective: To investigate the functional and quality of life (QoL) outcomes of treatments for localised prostate cancer and inform treatment decision-making. Patients And Methods: Men aged 50-69 years diagnosed with...
5.
Genkin M, Hughes O, Engel T
Nat Commun
. 2021 Oct;
12(1):5986.
PMID: 34645828
Many complex systems operating far from the equilibrium exhibit stochastic dynamics that can be described by a Langevin equation. Inferring Langevin equations from data can reveal how transient dynamics of...
6.
Hickey A, Stamou P, Udayan S, Ramon-Vazquez A, Esteban-Torres M, Bottacini F, et al.
Front Microbiol
. 2021 Jul;
12:653587.
PMID: 34220742
Exopolysaccharide (EPS) is a bacterial extracellular carbohydrate moiety which has been associated with immunomodulatory activity and host protective effects of several gut commensal bacteria. are early colonizers of the human...
7.
Bullock N, Ellul T, Biers S, Armitage J, Cashman S, Narahari K, et al.
BMC Med Educ
. 2020 Oct;
20(1):349.
PMID: 33028303
Background: Whilst competence in the management of a wide range of urological emergencies is a requirement for certification in urology, many conditions are uncommon and exposure during training may be...
8.
Wade J, Donovan J, Lane A, Davis M, Walsh E, Neal D, et al.
BMJ Open
. 2020 Sep;
10(9):e036024.
PMID: 32907896
Objectives: Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties...
9.
Hamdy F, Donovan J, Athene Lane J, Mason M, Metcalfe C, Holding P, et al.
Health Technol Assess
. 2020 Aug;
24(37):1-176.
PMID: 32773013
Background: Prostate cancer is the most common cancer among men in the UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well as undertreatment of the disease....
10.
Noble S, Garfield K, Athene Lane J, Metcalfe C, Davis M, Walsh E, et al.
Br J Cancer
. 2020 Jul;
123(7):1063-1070.
PMID: 32669672
Background: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. Methods: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within the Prostate Testing...